𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CQP 201-403 in Parkinson's disease: An open-label pilot study

✍ Scribed by Dr. Ronald F. Pfeiffer; Leonel H. Herrera; Carolyn S. Glaeske; Ruth E. Hofman

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
249 KB
Volume
4
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over a n average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201-403 may be of value in the treatment of Parkinson's disease.

πŸ“œ SIMILAR VOLUMES

Caffeine in Parkinson's disease: A pilot
Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
✍ Robert D. Altman; Anthony E. Lang; Ronald B. Postuma πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 314 KB πŸ‘ 1 views

## Abstract ## Introduction: Epidemiologic studies consistently find an inverse association between caffeine use and PD. Numerous explanations exist, but are difficult to evaluate as caffeine's symptomatic effect and tolerability in PD are unknown. ## Patients and Methods: We designed an open‐la

Symptomatic relief from treatment-induce
Symptomatic relief from treatment-induced psychosis in Parkinson's disease: An open-label pilot study with remoxipride
✍ Dr. Tilak Mendis; Erich Mohr; Amanda George; Ilene N. Rusk; Peggy Gray; J. David πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 320 KB πŸ‘ 1 views

## Abstract Current treatment strategies for levodopa‐induced psychosis in Parkinson's disease have had limited success. Remoxipride, a selective D~2~ receptor antagonist, was administered in an open label pilot study to seven parkinsonian patients exhibiting thought disorder. Symptoms improved sig

Atomoxetine for the treatment of executi
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study
✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 321 KB πŸ‘ 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi

An open-label conversion study of pramip
An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease
✍ Kelly E. Lyons; Rajesh Pahwa πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 103 KB

## Abstract Ropinirole prolonged release (PR) is a once daily oral dopamine agonist approved for the treatment of Parkinson's disease (PD). The goal of this 4 week, open‐label study was to determine the most effective conversion ratio with the fewest adverse effects (AEs) when switching from pramip

Open-label pilot study of levetiracetam
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
✍ Theresa A. Zesiewicz; Kelly L. Sullivan; John L. Maldonado; William O. Tatum; Ro πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 1 views

## Abstract We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and wer